RESUMO
The administration of cells as therapeutic agents has emerged as a novel approach to complement the use of small molecule drugs and other biologics for the treatment of numerous conditions. Although the use of cells for structural and/or functional tissue repair and regeneration provides new avenues to address increasingly complex disease processes, it also faces numerous challenges related to efficacy, safety, and translational potential. Recent advances in nanotechnology-driven cell therapies have the potential to overcome many of these issues through precise modulation of cellular behavior. Here, we describe several approaches that illustrate the use of different nanotechnologies for the optimization of cell therapies and discuss some of the obstacles that need to be overcome to allow for the widespread implementation of nanotechnology-based cell therapies in regenerative medicine.
Assuntos
Nanotecnologia , Medicina Regenerativa , Terapia Baseada em Transplante de Células e TecidosRESUMO
The outer capsid polypeptide, VP2, represents the major neutralizing antigen of infectious pancreatic necrosis virus (IPNV). A 926-bp viral cDNA, encoding an N-terminal truncated VP2, was cloned into the pWR590 expression plasmid family resulting in a C-terminal extension of a truncated Escherichia coli beta-galactosidase (beta Gal) under the control of the lac promoter. When cells transformed by in-phase hybrid plasmids were induced by isopropylthiogalactoside, high levels of the 100-kDa beta Gal-VP2 fusion protein accumulated within 4 h after induction. The fusion protein reacted in Western blots both with rabbit anti-beta Gal and with neutralizing mouse anti-VP2 monoclonal antibody. Sera of rabbits immunized with semipurified fusion protein reacted with the VP2 polypeptide in Western blots and with intact purified virus in ELISA and also neutralized IPNV infectivity in a plaque-reduction assay. Out-of-phase hybrid plasmids did not produce the fusion protein but expressed a small amount of structurally discrete VP2-specific sequences probably by internal initiation of translation at an in-phase AUG codon near the 5' end of the VP2 gene.
Assuntos
Capsídeo/genética , Clonagem Molecular , Escherichia coli/genética , Reoviridae/genética , Sequência de Aminoácidos , Animais , Antígenos Virais/biossíntese , Antígenos Virais/genética , Antígenos Virais/imunologia , Western Blotting , Proteínas do Capsídeo , Códon/genética , Dados de Sequência Molecular , Testes de Neutralização , Plasmídeos , Regiões Promotoras Genéticas , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Reoviridae/imunologia , Mapeamento por Restrição , Salmão/microbiologia , beta-Galactosidase/genéticaAssuntos
Neoplasias do Ânus , Melanoma , Neoplasias Retais , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
Although the number of reported cases of papillary carcinoma of the thyroid in families is few, a review of the literature and the three cases presented here strongly suggest the characteristics of hereditary cancer. Further study and reportage of similar cases is indicated to confirm whether this is indeed a familial cancer.
